Agilent Technologies, Inc. A
NYSE · Healthcare · Medical - Diagnostics & Research
$170.38
Close on Fri, 20 Nov 2026 · market value $48B
What the price is betting on
Priced for a lot to go rightAt $170, the price assumes revenue grows about 20% a year for five years, from $7.4B to about $15.8B by FY2030. That is about three times what analysts expect for the next two years and about seven times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 9.8% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than A? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$77
Base
$88
Bull
$100
Today $170
- Bear $77. Cash flow grows 4% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $88. Cash flow grows 7% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $100. Cash flow grows 9% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$7.7B$7.5B, on the path
- FY2027$9.2B$8B, below the path
- FY2028$11B$8.5B, below the path
- FY2029$13.2B$9.1B, below the path
- FY2030$15.8B$9.4B, below the path
Each year's revenue at 20% growth from $7.4B in the 12 months to July 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NYSE
- Revenue, FY2025
- $6.9B
- Growth, 3 years a year
- 2.8%
- Cash margin
- 17%
- Net debt
- $1.6B
- Shares, 3-year change
- −5.3%
- Dividend yield
- 0.6%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.